Spyre Therapeutics (NASDAQ:SYRE) Shares Gap Up Following Analyst Upgrade

Chronological Source Flow
Back

AI Fusion Summary

Spyre Therapeutics shares hit a new 52‑week high after Robert W. Baird raised its target from $65 to $90. The stock opened at $67.68, closed at $63.27, trading near $75.00. Mizuho and Leerink Partners upgraded the stock.
15/04 09:19 defenseworld.net
8 Πηγές
15/04 09:50 defenseworld.net
15/04 10:09 defenseworld.net
15/04 10:37 defenseworld.net
15/04 11:09 defenseworld.net
15/04 11:25 defenseworld.net
15/04 11:38 defenseworld.net
15/04 11:56 defenseworld.net
Comments
Loading...
0